3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Nasopharyngeal Carcinoma
16
Squamous Cell Carcinoma of Head and Neck
11
Esophageal Squamous Cell Carcinoma
11
Esophageal Neoplasms
9
Head and Neck Neoplasms
8
Uterine Cervical Neoplasms
7
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Pancreatic cancer, adult
2
Neoplasms
2
Nasopharyngeal Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Anal Canal
1
Solid Tumors
1
Solid Tumor
1
Resectable Pancreatic Cancer
1
Recurrence
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Cancer Resectable
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Diseases
1
NSCLC
1
Meningeal Carcinomatosis
1
Locally Advanced Rectal Cancer
1
Interventions
Gemcitabine
4
Taxes
3
S 1 (combination)
3
130-nm albumin-bound paclitaxel
3
toripalimab
2
Drug Therapy
2
Albumin-Bound Paclitaxel
2
surufatinib
1
nimotuzumab
1
envafolimab
1
endostar protein
1
conteltinib
1
camrelizumab
1
apatinib
1
Simvastatin
1
Radiosurgery
1
Nivolumab
1
Metformin
1
Immunotherapy
1
Endostatins
1
Digoxin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Pancreatic Cancer
×
nimotuzumab
×
Clear all
NCT06422156
2024-05-20
Nim-PC-28
Peking University Third Hospital
Phase 2
Unknown
73 enrolled